Active Head and Neck Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Head and Neck Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Head and Neck Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Head and Neck Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Head and Neck Cancer Clinical Trial FAQ

Does HPV status affect which head and neck cancer trials I qualify for?

Yes. HPV-positive oropharyngeal squamous cell carcinoma (typically p16-positive) has a better prognosis and different biology than HPV-negative disease. Some trials test whether HPV-positive patients can receive less intensive treatment (de-escalation trials) while maintaining high cure rates. HPV-negative head and neck cancer trials often focus on more aggressive combinations, including immunotherapy.

Are there head and neck cancer trials for patients who have already had surgery and radiation?

Yes. Trials in the adjuvant setting test new agents added to or replacing standard post-operative radiation with or without chemotherapy. For recurrent/metastatic disease after prior radiation, systemic therapy trials are available. Eligibility often depends on the dose of prior radiation received and time since treatment.

Can I join a head and neck cancer trial if my cancer has come back locally (not spread distantly)?

Locally recurrent head and neck cancer trials exist and may include re-irradiation approaches, stereotactic radiosurgery, or novel targeted therapies delivered locally. Eligibility depends on the site of recurrence, prior radiation dose, and whether the tumor is resectable. Systemic therapy trials may also enroll locally recurrent patients.

What is PD-L1 expression, and does it matter for head and neck cancer trial eligibility?

PD-L1 expression (measured by CPS — combined positive score) predicts response to pembrolizumab. A CPS ≥ 1 is required for some head and neck cancer indications, and higher CPS often predicts greater benefit. Many trials stratify patients by PD-L1 expression. PD-L1 testing is performed on your tumor tissue by pathology, and results should be in your medical record.

How does Trialify help head and neck cancer patients find trials near a major cancer center?

Enter your cancer site (oral cavity, oropharynx, larynx, etc.), HPV status, and ZIP code on Trialify. We search ClinicalTrials.gov and sort results by distance from your location. The eligibility questionnaire covers HPV status, PD-L1 score, and prior treatment history in plain language so you know exactly what to discuss with your oncologist.

Explore Other Cancer Trial Guides

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.